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Letter to the Editor
SARS-CoV-2: “Three-steps” infection model and CSF diagnostic implication
Dear Editor,
An increasing number of Coronavirus Disease 2019 (COVID-19)
patients shows neurological symptoms, but currently few studies have
systematically analyzed the impact of SARS-CoV-2 on the Central
Nervous System (CNS). Symptoms are usually mild like headache, an-
osmia and dysgeusia, although disturbance of consciousness, paralysis,
paraesthesia and seizures have also been described (Mao et al., 2020).
Interestingly, severe neurological complications could appear delayed
to respiratory symptoms (Bertran Recasens et al., 2020).
In our Department we observed 3 different clinical pictures in SARS-
CoV-2 infection with neurological impairment: cerebral thrombosis
(CTh) with hemorrhagic infarction, demyelinating lesions (Zanin et al.,
2020) and encephalopathy. We defined this condition as Neuro-COVID
for the overwhelming CNS involvement in COVID-19.
Currently the diagnosis of SARS-CoV-2 infection is based on real-
time reverse-transcription polymerase chain reaction (rRT-PCR) per-
formed on nasopharyngeal swab. However, the sensitivity of this
method is about 60% (Wang et al., 2020). Therefore, a negative rRT-
PCR does not exclude a SARS-CoV-2 infection. The diagnostic work-up
for Neuro-COVID is even more challenging. Neuroimaging cannot al-
ways provide a diagnostic certainty. A lumbar puncture could add re-
levant data to the diagnostic process but this test is rarely positive (Ye
et al., 2020). This could be explained by the mechanism of CNS inva-
sion by SARS-CoV-2 and the resulting pathophysiologic events.
SARS-CoV-2 may lead to Neuro-COVID through three phases
(Fig. 1): neuroinvasion, CNS clearance and immune response.
1) The SARS-CoV-2 reaches the brain via the bloodstream and/or trans-
cribriform route along the olfactory nerve. The viral load in the
cerebrospinal fluid (CSF) should progressively increase till the
second phase.
2) The interaction between the spike protein S1 and the host ACE-2
receptor allows the penetration of SARS-CoV-2 into the neuronal
cells (Mao et al., 2020). This mechanism determines a direct neu-
ronal damage and the onset of symptoms such as anosmia and
dysgeusia even in the early phase of infection (Mao et al., 2020).
Nevertheless, a severe respiratory impairment could be observed in
case of nucleus of the solitary tract involvement (Bertran Recasens
et al., 2020). During the CNS clearance phase the viral load starts to
Fig. 1. According to pre-clinical model based on
SARS-CoV, in the first phase of neuroinvasion the
virus follows a trans-synaptic pathway along the
olfactory nerve reaching the entorhinal cortex.
Minimal or no respiratory symptoms are detected
and CoV replication increases the viral load in CSF
(blue curve). In the “CNS clearance” phase, CoV
could be located in the brainstem (e.g. nucleus of
the solitary tract) affecting the respiratory drive.
The viral load in CSF progressively decreases but,
on the contrary, SARS-CoV-2 could be detected in
respiratory secretions by nasopharyngeal swab
(yellow hyperbole). In the last phase, the respiratory
system is severely affected leading to potential hy-
poxia with subsequent brain damage. IP, Interstitial
pneumonia. (For interpretation of the references to
colour in this figure legend, the reader is referred to
the web version of this article.)
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decrease till the occurrence of the indirect SARS-CoV-2 effects on
the CNS.
3) The viral infection can lead to an immuno-mediated central nervous
system damage. Moreover, SARS-CoV-2 could trigger the production
of antibodies against glial cells, as a para-infective or post-infective
phenomenon, similarly to Epstein Barr Virus. In this phase the re-
spiratory system could be severely affected leading to neurotoxic
hypoxia with subsequent brain damage.
The Neuro-COVID clinical pictures generally occur in the last phase
with different phenotypes (CTh, demyelinating lesions and encephalo-
pathy). Nevertheless, the SARS-CoV-2 load could be significantly re-
duced and not detectable in the CSF. Negative results could also be
explained by the lack of apoptosis and/or necrosis as observed in pre-
clinical models (Netland et al., 2008), the low-sensitivity of the method
and the CSF clearance of SARS-CoV-2 that lead to a low viral below the
sensitivity of currently available instrumentation.
Neuro-COVID could be a severe, occasionally fatal, delayed com-
plication of SARS-CoV-2. Prompt invasive treatment could be required
to hypoxia with possible neurological impairment. Diagnosis is mainly
based on clinical pictures and neuroimaging; on the other hand, CSF
analysis generally fails to reveal SARS-CoV-2 and should not be con-
sidered mandatory for the treatment.
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